Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
In this protocol, we plan to identify specific markers from nuclear magnetic resonance
(NMR)biochemical and molecular genetic analysis that predict clinical outcome and
responsiveness to therapy in patients with soft tissue sarcoma. Although most sarcomas
rarely present diagnostic dilemmas because each has consistent morphologic and cytogenetic
features that can readily be identified, it is not possible with conventional methods to
predict what the clinical outcome will be for each individual patient, or how a given tumor
will respond to neoadjuvant therapy. Thus,new methods for assessing the potential of these
tumors to recur or metastasize and respond to therapy will result in real benefits for
patients with these sarcomas.
Observational Model: Case Control, Time Perspective: Prospective
Analyze NMR biochemical and molecular patterns from oligonucleotide, SNP and CGH arrays to identify markers that can provide an objective measure of sarcoma differentiation, cellularity, proliferation, necrosis and apoptosis.
Singer Singer, M.D.
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|